{"component": "definition", "props": {"groups": [{"size": 2, "snippet": "[\u2020]. If Omeros elects and directs Affitech in writing to have Affitech complete [\u2020]. Deliverable data and reagents: [\u2020].", "snippet_links": [{"key": "in-writing", "type": "clause", "offset": [43, 53]}, {"key": "deliverable-data", "type": "definition", "offset": [85, 101]}], "samples": [{"hash": "iwPTDrywX4j", "uri": "/contracts/iwPTDrywX4j#milestone-ii", "label": "Agreement for Antibody Discovery and Development (Omeros Corp)", "score": 21.0, "published": true}, {"hash": "h6hWqVzmB38", "uri": "/contracts/h6hWqVzmB38#milestone-ii", "label": "Agreement for Antibody Discovery and Development (Omeros Corp)", "score": 21.0, "published": true}], "hash": "aafbc547235e02d2615e1dbdd95f2c6e", "id": 1}, {"size": 2, "snippet": "means the date on which Company shall have raised an aggregate of Three Million Dollars ($3,000,000) in equity financing following the Effective Date.", "snippet_links": [{"key": "equity-financing", "type": "definition", "offset": [104, 120]}, {"key": "following-the-effective-date", "type": "clause", "offset": [121, 149]}], "samples": [{"hash": "lDW9kWbCHNp", "uri": "/contracts/lDW9kWbCHNp#milestone-ii", "label": "Employment Agreement (Roughneck Supplies Inc.)", "score": 21.0, "published": true}, {"hash": "7jIi0Rp97vB", "uri": "/contracts/7jIi0Rp97vB#milestone-ii", "label": "Employment Agreement (Roughneck Supplies Inc.)", "score": 21.0, "published": true}], "hash": "2f9d81dbd7b3b338214dee2d1f324929", "id": 2}, {"size": 2, "snippet": "means receipt by Bank of evidence reasonably satisfactory to Bank of Parent\u2019s receipt after the Closing Date of at least $62,350,000 of net proceeds from the sale or issuance of its equity securities on or before April 30, 2019 to investors reasonably acceptable to Bank.", "snippet_links": [{"key": "bank-of", "type": "definition", "offset": [17, 24]}, {"key": "to-bank", "type": "definition", "offset": [58, 65]}, {"key": "date-of", "type": "clause", "offset": [104, 111]}, {"key": "net-proceeds", "type": "clause", "offset": [136, 148]}, {"key": "the-sale", "type": "clause", "offset": [154, 162]}, {"key": "equity-securities", "type": "clause", "offset": [182, 199]}, {"key": "before-april", "type": "clause", "offset": [206, 218]}], "samples": [{"hash": "hQKMjFEH88z", "uri": "/contracts/hQKMjFEH88z#milestone-ii", "label": "Loan and Security Agreement (Compass Therapeutics, Inc.)", "score": 26.4750175476, "published": true}], "hash": "3c39ebb3aec54318ee43a7a88663eefe", "id": 3}, {"size": 1, "snippet": "the effecting of a First Commercial Sale by no later than forty-two (42) months from the Effective Date.", "snippet_links": [{"key": "first-commercial-sale", "type": "clause", "offset": [19, 40]}, {"key": "from-the-effective-date", "type": "clause", "offset": [80, 103]}], "samples": [{"hash": "bpRmF57L9VV", "uri": "/contracts/bpRmF57L9VV#milestone-ii", "label": "License Agreement (Traceguard Technologies, Inc.)", "score": 18.0, "published": true}], "hash": "1e01b1971246d4d1e212279c40c59bf7", "id": 4}, {"size": 1, "snippet": "means [*] referred to in Section 5.2(b) hereof. ------------ --------------", "snippet_links": [], "samples": [{"hash": "3ER3Ly6KRs9", "uri": "/contracts/3ER3Ly6KRs9#milestone-ii", "label": "Supply Agreement (Immunex Corp /De/)", "score": 18.0, "published": true}], "hash": "608c8888028caaaa2c2fab154bbb0bf1", "id": 5}, {"size": 1, "snippet": "First Commercial Sale (as such term shall be defined in the License Agreement) of the Product in the USA - by no later than eighteen (18) months from receipt of regulatory approval by TSA to sell the Product in the USA. IBHS shall use reasonable efforts to promote the development and commercialization efforts with respect to the Product.", "snippet_links": [{"key": "first-commercial-sale", "type": "clause", "offset": [0, 21]}, {"key": "the-license-agreement", "type": "clause", "offset": [56, 77]}, {"key": "the-product", "type": "definition", "offset": [82, 93]}, {"key": "approval-by", "type": "clause", "offset": [172, 183]}, {"key": "to-sell", "type": "clause", "offset": [188, 195]}, {"key": "reasonable-efforts", "type": "clause", "offset": [235, 253]}, {"key": "development-and-commercialization-efforts", "type": "clause", "offset": [269, 310]}, {"key": "with-respect-to", "type": "clause", "offset": [311, 326]}], "samples": [{"hash": "gkbEgabckfP", "uri": "/contracts/gkbEgabckfP#milestone-ii", "label": "Letter of Intent (Ibhas Technologies Inc)", "score": 16.0, "published": true}], "hash": "00e2ce0591fa6e42437266286316e1fe", "id": 6}, {"size": 1, "snippet": "means the closing of an equity round of financing, after the date hereof with net proceeds received by the Company of at least $10,000,000, and future commitments of at least an additional $10,000,000; and", "snippet_links": [{"key": "the-closing", "type": "definition", "offset": [6, 17]}, {"key": "equity-round", "type": "definition", "offset": [24, 36]}, {"key": "date-hereof", "type": "clause", "offset": [61, 72]}, {"key": "net-proceeds", "type": "clause", "offset": [78, 90]}, {"key": "received-by-the-company", "type": "definition", "offset": [91, 114]}, {"key": "future-commitments", "type": "clause", "offset": [144, 162]}, {"key": "an-additional", "type": "clause", "offset": [175, 188]}], "samples": [{"hash": "9Mdo9bt6kS9", "uri": "/contracts/9Mdo9bt6kS9#milestone-ii", "label": "Loan Agreement (Corautus Genetics Inc)", "score": 21.0, "published": true}], "hash": "0e164d6a1d89a3a1845e7b968baeb776", "id": 7}, {"size": 1, "snippet": "EMPLOYEE shall have caused EMPLOYER to reach final agreements on the installation of MR3 plants to process EAF on the properties of two additional steel companies on or before December 31, 2001, processing no less than a total of 50,000 tons of EAF per year. EMPLOYEE shall be responsible for monitoring the prioritization of these duties, with first priority and emphasis on reaching the Milestones set forth above. Should EMPLOYEE determine that EMPLOYER is jeopardizing EMPLOYEE's ability to reach these Milestones by asking EMPLOYEE to devote time to lesser priority items, EMPLOYEE shall notify EMPLOYER immediately. Any material change in the priority listed above shall then result in a change in the timing of the Milestones, upon mutual agreement between EMPLOYER and EMPLOYEE. EXHIBIT \"B\" ----------- CONFIDENTIALITY AGREEMENT THIS AGREEMENT is made and entered into this 15th day of September, 2000, by and between: MR3 Systems, Inc. (\"EMPLOYER \"), a Delaware corporation, whose address is \u2587\u2587\u2587\u2587 \u2587\u2587, \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587, and \u2587\u2587\u2587\u2587\u2587 \u2587. \u2587\u2587\u2587\u2587\u2587\u2587 (\"EMPLOYEE\"), whose address is \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587 \u2587\u2587\u2587\u2587\u2587. EMPLOYER and EMPLOYEE, respectively, may each from time to time be individually referred to herein as a \"Party\", or collectively as the \"Parties\", or, as the case may be, as the \"EMPLOYER\" or the \"EMPLOYEE\".", "snippet_links": [{"key": "final-agreements", "type": "clause", "offset": [45, 61]}, {"key": "installation-of", "type": "clause", "offset": [69, 84]}, {"key": "the-properties", "type": "definition", "offset": [114, 128]}, {"key": "before-december", "type": "clause", "offset": [169, 184]}, {"key": "per-year", "type": "definition", "offset": [249, 257]}, {"key": "responsible-for", "type": "clause", "offset": [277, 292]}, {"key": "first-priority", "type": "clause", "offset": [345, 359]}, {"key": "the-milestones", "type": "clause", "offset": [385, 399]}, {"key": "ability-to", "type": "clause", "offset": [484, 494]}, {"key": "material-change", "type": "clause", "offset": [626, 641]}, {"key": "a-change-in", "type": "definition", "offset": [692, 703]}, {"key": "timing-of-the", "type": "clause", "offset": [708, 721]}, {"key": "agreement-between", "type": "clause", "offset": [746, 763]}, {"key": "employer-and-employee", "type": "clause", "offset": [764, 785]}, {"key": "confidentiality-agreement", "type": "definition", "offset": [811, 836]}, {"key": "this-agreement", "type": "clause", "offset": [837, 851]}, {"key": "entered-into", "type": "clause", "offset": [864, 876]}, {"key": "day-of", "type": "clause", "offset": [887, 893]}, {"key": "delaware-corporation", "type": "definition", "offset": [962, 982]}, {"key": "from-time-to-time", "type": "clause", "offset": [1187, 1204]}, {"key": "the-case", "type": "definition", "offset": [1295, 1303]}], "samples": [{"hash": "9sJ2gMioNod", "uri": "/contracts/9sJ2gMioNod#milestone-ii", "label": "Employment Agreement (Mr3 Systems Inc)", "score": 16.0, "published": true}], "hash": "6e3759efb48bb28c5bb410926e2597ee", "id": 8}, {"size": 1, "snippet": "means the Successful Completion of the U.S. Phase III Clinical Study.", "snippet_links": [{"key": "the-us", "type": "clause", "offset": [35, 42]}, {"key": "phase-iii-clinical-study", "type": "definition", "offset": [44, 68]}], "samples": [{"hash": "4wZrgwEdPf7", "uri": "/contracts/4wZrgwEdPf7#milestone-ii", "label": "Stock Purchase Agreement (Amarin Corp Plc\\uk)", "score": 21.0, "published": true}], "hash": "f7557ac29fdba8bf881b7fb71247daab", "id": 9}, {"size": 1, "snippet": "means [***].", "snippet_links": [], "samples": [{"hash": "fBGAZhY40lX", "uri": "/contracts/fBGAZhY40lX#milestone-ii", "label": "Preferred Stock Purchase Agreement (Painreform Ltd.)", "score": 36.5208761123, "published": true}], "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 10}], "next_curs": "ClkSU2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjULEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIVbWlsZXN0b25lLWlpIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 15, "snippet": "[\u2020]. If Omeros elects and directs Affitech in writing to have Affitech complete [\u2020]. Deliverable data and reagents: [\u2020].", "title": "Milestone II", "id": "milestone-ii", "examples": ["In the event that Seller cannot meet either <strong>Milestone II</strong> or Milestone III due to delays caused by Buyer, Seller\u2019s sole remedy will be an extension of Milestone III for up to three months, as determined by the Buyer at Buyer\u2019s sole discretion.", "Prior to Buyer granting an extension for <strong>Milestone II</strong> and III, Seller must provide evidence that any letter of credit or other performance security is active and available for the remainder of the Agreement Term.", "In addition, each Research Plan will set forth the criteria for achieving the Technical <strong>Milestone II</strong> Criteria described in Section 4.2(b) (Technical Milestone), which criteria shall be of the type that Adimab currently has the capability of analytically measuring, such as affinity and epitopic coverage, and such attributes shall not include any sort of measurement of biological functionality.", "Subject to the terms and conditions of this Agreement, beginning on Borrower\u2019s achievement of Performance <strong>Milestone II</strong> and continuing through June 30, 2021, Borrower may request and the Lenders shall severally (and not jointly) make an additional Term Loan Advance in a principal amount of Ten Million Dollars ($10,000,000), (the \u201cTranche 3 Advance\u201d).", "A Compound which is identified by the Joint Research Committee as meeting the criteria in Attachment 2.1 set for <strong>Milestone II</strong> will be reviewed by Merck&#x27;s internal system for acceptance of such Compound as a Safety Assessment Candidate.", "In the event that the Technical <strong>Milestone II</strong> Criteria are met and the payment under Section 4.2(b)(i) (Technical Milestone I) has not yet been paid to Adimab with respect to such Research Program, iTeos shall also make the payment under Section 4.2(b)(i) (Technical Milestone I) simultaneously with the payment under this Section 4.2(b)(ii) (Technical <strong>Milestone II</strong>).", "Notwithstanding the foregoing, the amount due to Adimab from iTeos with respect to the second and third Research Programs in which the Technical <strong>Milestone II</strong> Criteria are met shall be [***] rather than the [***] which would otherwise be payable.", "On a Research Program-by-Research Program basis, iTeos shall pay Adimab [***] within [***] of Adimab\u2019s delivery to iTeos of a panel of Program Antibodies meeting pre-agreed goals as set forth in the Research Plan, which goals shall be of the type typically measured by Adimab\u2019s protein analytics group, including affinity, specificity, and epitopic coverage (the \u201cTechnical <strong>Milestone II</strong> Criteria\u201d).", "Subject to the terms and conditions of this Agreement, beginning on the date Borrower achieves Performance <strong>Milestone II</strong> and continuing through June 30, 2022, Borrower may request and Lenders severally (and not jointly) will make Term Loan Advances in an aggregate amount up to $7,500,000, in minimum increments of $2,500,000, or if the undrawn amount of the Tranche 3 Term Loan is less than $2,500,000, such lesser amount (each, a \u201cTranche 3 Term Loan Advance\u201d).", "For the avoidance of doubt, if the Tranche 2 Advance is not drawn or Borrower has achieved Performance <strong>Milestone II</strong> by September 30, 2021, then there shall be no minimum cash requirement."], "related": [["milestone-2", "Milestone 2", "Milestone 2"], ["milestone-1", "Milestone 1", "Milestone 1"], ["milestone", "Milestone", "Milestone"], ["milestone-date", "Milestone Date", "Milestone Date"], ["development-milestone-payment", "Development Milestone Payment", "Development Milestone Payment"]], "related_snippets": [], "updated": "2025-07-12T04:23:56+00:00"}, "json": true, "cursor": ""}}